[1]
Ahmed, R.M. et al. 2016. Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery & Psychiatry. 87, 11 (Nov. 2016), 1234–1241. DOI:https://doi.org/10.1136/jnnp-2014-308350.
[2]
Alzheimer’s Facts and Figures Report | Alzheimer’s Association: https://www.alz.org/alzheimers-dementia/facts-figures.
[3]
Arash Asher The effect of cancer treatment on cognitive function. undefined.
[4]
Barker, R.A. and Williams-Gray, C.H. 2016. Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology. 42, 1 (Feb. 2016), 6–19. DOI:https://doi.org/10.1111/nan.12303.
[5]
Bates, G.P. et al. 2015. Huntington disease. Nature Reviews Disease Primers. (Apr. 2015). DOI:https://doi.org/10.1038/nrdp.2015.5.
[6]
Blennow, K. et al. 2012. The Neuropathology and Neurobiology of Traumatic Brain Injury. Neuron. 76, 5 (Dec. 2012), 886–899. DOI:https://doi.org/10.1016/j.neuron.2012.11.021.
[7]
Braak, H. and Braak, E. 1995. Staging of alzheimer’s disease-related neurofibrillary changes. Neurobiology of Aging. 16, 3 (May 1995), 271–278. DOI:https://doi.org/10.1016/0197-4580(95)00021-6.
[8]
Bras, J. et al. 2014. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics. 23, 23 (Dec. 2014), 6139–6146. DOI:https://doi.org/10.1093/hmg/ddu334.
[9]
Carroll, J.B. et al. 2015. Treating the whole body in Huntington’s disease. The Lancet Neurology. 14, 11 (Nov. 2015), 1135–1142. DOI:https://doi.org/10.1016/S1474-4422(15)00177-5.
[10]
Clarke, C. et al. eds. 2016. Neurology: a Queen Square textbook. Wiley Blackwell.
[11]
Collinge, J. 2016. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 539, 7628 (Nov. 2016), 217–226. DOI:https://doi.org/10.1038/nature20415.
[12]
De Chiara, G. et al. 2012. Infectious Agents and Neurodegeneration. Molecular Neurobiology. 46, 3 (Dec. 2012), 614–638. DOI:https://doi.org/10.1007/s12035-012-8320-7.
[13]
Devenney, E. et al. 2015. Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Review of Neurotherapeutics. 15, 5 (May 2015), 509–522. DOI:https://doi.org/10.1586/14737175.2015.1034108.
[14]
Dobson, R. and Alvares, D. 2016. The difficulties with vitamin B. Practical Neurology. 16, 4 (Aug. 2016), 308–311. DOI:https://doi.org/10.1136/practneurol-2015-001344.
[15]
Dubois, B. et al. 2014. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. The Lancet Neurology. 13, 6 (Jun. 2014), 614–629. DOI:https://doi.org/10.1016/S1474-4422(14)70090-0.
[16]
Fleminger, S. 2003. Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication. Journal of Neurology, Neurosurgery & Psychiatry. 74, 7 (Jul. 2003), 857–862. DOI:https://doi.org/10.1136/jnnp.74.7.857.
[17]
Fletcher, P.D. and Warren, J.D. 2011. Semantic Dementia: a specific network-opathy. Journal of Molecular Neuroscience. 45, 3 (Nov. 2011), 629–636. DOI:https://doi.org/10.1007/s12031-011-9586-3.
[18]
Ghanem, K.G. 2010. REVIEW: Neurosyphilis: A Historical Perspective and Review. CNS Neuroscience & Therapeutics. 16, 5 (Oct. 2010), e157–e168. DOI:https://doi.org/10.1111/j.1755-5949.2010.00183.x.
[19]
Goll, J.C. et al. 2010. Central auditory disorders: toward a neuropsychology of auditory objects. Current Opinion in Neurology. 23, 6 (Dec. 2010), 617–627. DOI:https://doi.org/10.1097/WCO.0b013e32834027f6.
[20]
Goll, J.C. et al. 2012. Nonverbal sound processing in semantic dementia: A functional MRI study. NeuroImage. 61, 1 (May 2012), 170–180. DOI:https://doi.org/10.1016/j.neuroimage.2012.02.045.
[21]
Goll, J.C. et al. 2010. Non-verbal sound processing in the primary progressive aphasias. Brain. 133, 1 (Jan. 2010), 272–285. DOI:https://doi.org/10.1093/brain/awp235.
[22]
Gordon, E. et al. 2016. Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry. 138, (Aug. 2016), 193–210. DOI:https://doi.org/10.1111/jnc.13656.
[23]
Gorelick, P.B. et al. 2011. Vascular Contributions to Cognitive Impairment and Dementia. Stroke. 42, 9 (Sep. 2011), 2672–2713. DOI:https://doi.org/10.1161/STR.0b013e3182299496.
[24]
Gorno-Tempini, M.L. et al. 2011. Classification of primary progressive aphasia and its variants. Neurology. 76, 11 (Mar. 2011), 1006–1014. DOI:https://doi.org/10.1212/WNL.0b013e31821103e6.
[25]
Graus, F. et al. 2016. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 15, 4 (Apr. 2016), 391–404. DOI:https://doi.org/10.1016/S1474-4422(15)00401-9.
[26]
Graus, F. et al. 2016. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 15, 4 (Apr. 2016), 391–404. DOI:https://doi.org/10.1016/S1474-4422(15)00401-9.
[27]
Green, A.J.E. 2018. RT-QuIC: a new test for sporadic CJD. Practical Neurology. (Oct. 2018). DOI:https://doi.org/10.1136/practneurol-2018-001935.
[28]
Grossman, M. 2012. The non-fluent/agrammatic variant of primary progressive aphasia. The Lancet Neurology. 11, 6 (Jun. 2012), 545–555. DOI:https://doi.org/10.1016/S1474-4422(12)70099-6.
[29]
Hachinski, V. et al. 2006. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke. 37, 9 (Sep. 2006), 2220–2241. DOI:https://doi.org/10.1161/01.STR.0000237236.88823.47.
[30]
Haddow, L.J. et al. 2013. HIV and the brain: from AIDS to old age. Clinical Medicine. 13, Suppl_6 (Dec. 2013), s24–s28. DOI:https://doi.org/10.7861/clinmedicine.13-6-s24.
[31]
Halliday, G.M. et al. 2011. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica. 122, 2 (Aug. 2011), 187–204. DOI:https://doi.org/10.1007/s00401-011-0852-9.
[32]
Halperin, J.J. et al. 2015. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. Neurology. 85, 23 (Dec. 2015), 2063–2071. DOI:https://doi.org/10.1212/WNL.0000000000002193.
[33]
Hardy, C.J.D. et al. 2016. Hearing and dementia. Journal of Neurology. 263, 11 (Nov. 2016), 2339–2354. DOI:https://doi.org/10.1007/s00415-016-8208-y.
[34]
Hereditary and sporadic beta-amyloidoses: https://www.bioscience.org/2013/v18/af/4173/fulltext.htm.
[35]
HIV in the United Kingdom 2016 infographic: https://www.gov.uk/government/publications/hiv-in-the-united-kingdom.
[36]
Hodges, J.R. 2017. Cognitive assessment for clinicians. Oxford University Press.
[37]
Hollak, C.E.M. and Lachmann, R. eds. 2016. Inherited metabolic disease in adults: a clinical guide. Oxford University Press.
[38]
Husain, M. 2016. Oxford textbook of cognitive neurology and dementia. Oxford University Press.
[39]
Husain, M. 2016. Oxford textbook of cognitive neurology and dementia. Oxford University Press.
[40]
Iranzo, A. et al. 2014. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE. 9, 2 (Feb. 2014). DOI:https://doi.org/10.1371/journal.pone.0089741.
[41]
Itzhaki, R.F. et al. 2016. Microbes and Alzheimer’s Disease. Journal of Alzheimer’s Disease. 51, 4 (Apr. 2016), 979–984. DOI:https://doi.org/10.3233/JAD-160152.
[42]
Johnson, G.V.W. 2004. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science. 117, 24 (Nov. 2004), 5721–5729. DOI:https://doi.org/10.1242/jcs.01558.
[43]
Johnson, K.A. et al. 2012. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine. 2, 4 (Apr. 2012), a006213–a006213. DOI:https://doi.org/10.1101/cshperspect.a006213.
[44]
Jonathan Carr 2003. Neurosyphilis. Practical Neurology. 3, (Dec. 2003), 328–341.
[45]
Jones, L. et al. 2017. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology. 16, 1 (Jan. 2017), 88–96. DOI:https://doi.org/10.1016/S1474-4422(16)30350-7.
[46]
Kandel, E.R. et al. eds. 2013. Principles of neural science. McGraw Hill Medical.
[47]
Karran, E. and Hardy, J. 2014. Antiamyloid Therapy for Alzheimer’s Disease — Are We on the Right Road? New England Journal of Medicine. 370, 4 (Jan. 2014), 377–378. DOI:https://doi.org/10.1056/NEJMe1313943.
[48]
Kielb, S.A. et al. 2012. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. NeuroMolecular Medicine. 14, 3 (Sep. 2012), 180–193. DOI:https://doi.org/10.1007/s12017-012-8182-1.
[49]
Leys, D. et al. 2005. Poststroke dementia. The Lancet Neurology. 4, 11 (Nov. 2005), 752–759. DOI:https://doi.org/10.1016/S1474-4422(05)70221-0.
[50]
Leyton, C.E. et al. 2015. Is the logopenic-variant of primary progressive aphasia a unitary disorder? Cortex. 67, (Jun. 2015), 122–133. DOI:https://doi.org/10.1016/j.cortex.2015.03.011.
[51]
Livingston, G. et al. 2017. Dementia prevention, intervention, and care. The Lancet. 390, 10113 (Dec. 2017), 2673–2734. DOI:https://doi.org/10.1016/S0140-6736(17)31363-6.
[52]
Loy, C.T. et al. 2014. Genetics of dementia. The Lancet. 383, 9919 (Mar. 2014), 828–840. DOI:https://doi.org/10.1016/S0140-6736(13)60630-3.
[53]
Lynch, D.S. et al. 2017. Clinical and genetic characterization of leukoencephalopathies in adults. Brain. 140, 5 (May 2017), 1204–1211. DOI:https://doi.org/10.1093/brain/awx045.
[54]
Mander, B.A. et al. 2016. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer’s Disease? Trends in Neurosciences. 39, 8 (Aug. 2016), 552–566. DOI:https://doi.org/10.1016/j.tins.2016.05.002.
[55]
Marshall, C.R. et al. 2018. Primary progressive aphasia: a clinical approach. Journal of Neurology. 265, 6 (Jun. 2018), 1474–1490. DOI:https://doi.org/10.1007/s00415-018-8762-6.
[56]
McCarter, S.J. et al. 2016. Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports. 16, 9 (Sep. 2016). DOI:https://doi.org/10.1007/s11910-016-0680-3.
[57]
McCarthy, R.A. and Warrington, E.K. 1990. Cognitive neuropsychology: a clinical introduction. Academic Press, Inc.
[58]
McKee, A.C. et al. 2013. The spectrum of disease in chronic traumatic encephalopathy. Brain. 136, 1 (Jan. 2013), 43–64. DOI:https://doi.org/10.1093/brain/aws307.
[59]
McKeith, I.G. et al. 2017. Diagnosis and management of dementia with Lewy bodies. Neurology. 89, 1 (Jul. 2017), 88–100. DOI:https://doi.org/10.1212/WNL.0000000000004058.
[60]
Mead, S. and Rudge, P. 2017. CJD mimics and chameleons. Practical Neurology. 17, 2 (Apr. 2017), 113–121. DOI:https://doi.org/10.1136/practneurol-2016-001571.
[61]
Mirra, S.S. et al. 1991. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 41, 4 (Apr. 1991), 479–479. DOI:https://doi.org/10.1212/WNL.41.4.479.
[62]
Montine, T.J. et al. 2012. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica. 123, 1 (Jan. 2012), 1–11. DOI:https://doi.org/10.1007/s00401-011-0910-3.
[63]
Montine, T.J. et al. 2012. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica. 123, 1 (Jan. 2012), 1–11. DOI:https://doi.org/10.1007/s00401-011-0910-3.
[64]
Nightingale, S. et al. 2014. Controversies in HIV-associated neurocognitive disorders. The Lancet Neurology. 13, 11 (Nov. 2014), 1139–1151. DOI:https://doi.org/10.1016/S1474-4422(14)70137-1.
[65]
Nightingale, S. et al. 2013. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. Practical Neurology. 13, 6 (Dec. 2013), 354–356. DOI:https://doi.org/10.1136/practneurol-2013-000689.
[66]
O’Brien, J.T. and Thomas, A. 2015. Vascular dementia. The Lancet. 386, 10004 (Oct. 2015), 1698–1706. DOI:https://doi.org/10.1016/S0140-6736(15)00463-8.
[67]
Ooms, S. and Ju, Y.-E. 2016. Treatment of Sleep Disorders in Dementia. Current Treatment Options in Neurology. 18, 9 (Sep. 2016). DOI:https://doi.org/10.1007/s11940-016-0424-3.
[68]
Revesz, T. et al. 2009. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica. 118, 1 (Jul. 2009), 115–130. DOI:https://doi.org/10.1007/s00401-009-0501-8.
[69]
Richard W. Price and Bruce J. Brew 1988. The AIDS Dementia Complex. The Journal of Infectious Diseases. 158, 5 (1988).
[70]
Rohrer, J.D. et al. 2010. Progressive logopenic/phonological aphasia: Erosion of the language network. NeuroImage. 49, 1 (Jan. 2010), 984–993. DOI:https://doi.org/10.1016/j.neuroimage.2009.08.002.
[71]
Rohrer, J.D. et al. 2012. Receptive prosody in nonfluent primary progressive aphasias. Cortex. 48, 3 (Mar. 2012), 308–316. DOI:https://doi.org/10.1016/j.cortex.2010.09.004.
[72]
Rohrer, J.D. et al. 2010. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. Neurology. 75, 7 (Aug. 2010), 603–610. DOI:https://doi.org/10.1212/WNL.0b013e3181ed9c6b.
[73]
Rohrer, J.D. et al. 2007. Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain. 131, 1 (Dec. 2007), 8–38. DOI:https://doi.org/10.1093/brain/awm251.
[74]
Ross, C.A. et al. 2014. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology. 10, 4 (Apr. 2014), 204–216. DOI:https://doi.org/10.1038/nrneurol.2014.24.
[75]
Rossor, M. et al. 2016. Dementia and Cognitive Impairment. Neurology. C. Clarke et al., eds. John Wiley & Sons, Ltd. 289–336.
[76]
Rossor, M. and Growdon, J.H. 2007. The dementias 2. Butterworth Heinemann/Elsevier.
[77]
Rossor, M.N. et al. 2010. The diagnosis of young-onset dementia. The Lancet Neurology. 9, 8 (Aug. 2010), 793–806. DOI:https://doi.org/10.1016/S1474-4422(10)70159-9.
[78]
Salvarani, C. et al. 2012. Adult primary central nervous system vasculitis. The Lancet. 380, 9843 (Aug. 2012), 767–777. DOI:https://doi.org/10.1016/S0140-6736(12)60069-5.
[79]
Schott, J.M. et al. 2016. Assessment and investigation of the cognitively impaired adult. Oxford Textbook of Cognitive Neurology and Dementia. M. Husain and J.M. Schott, eds. Oxford University Press. 221–230.
[80]
Scott, G. et al. 2016. Amyloid pathology and axonal injury after brain trauma. Neurology. 86, 9 (Mar. 2016), 821–828. DOI:https://doi.org/10.1212/WNL.0000000000002413.
[81]
Selkoe, D.J. and Hardy, J. 2016. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine. 8, 6 (Jun. 2016), 595–608. DOI:https://doi.org/10.15252/emmm.201606210.
[82]
Smith, D.H. et al. 2013. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nature Reviews Neurology. 9, 4 (Apr. 2013), 211–221. DOI:https://doi.org/10.1038/nrneurol.2013.29.
[83]
Somasundaram, O. 2009. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. Indian Journal of Psychiatry. 51, 3 (2009). DOI:https://doi.org/10.4103/0019-5545.55103.
[84]
Strong, M.J. et al. 2017. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18, 3–4 (Apr. 2017), 153–174. DOI:https://doi.org/10.1080/21678421.2016.1267768.
[85]
Tabrizi, S.J. et al. 2011. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology. 10, 1 (Jan. 2011), 31–42. DOI:https://doi.org/10.1016/S1474-4422(10)70276-3.
[86]
Tabrizi, S.J. et al. 2012. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology. 11, 1 (Jan. 2012), 42–53. DOI:https://doi.org/10.1016/S1474-4422(11)70263-0.
[87]
Tabrizi, S.J. et al. 2013. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet Neurology. 12, 7 (Jul. 2013), 637–649. DOI:https://doi.org/10.1016/S1474-4422(13)70088-7.
[88]
Thal, D.R. 2004. Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment. 2004, 23 (Jun. 2004), pe26–pe26. DOI:https://doi.org/10.1126/sageke.2004.23.pe26.
[89]
UK National Guidelines for HIV Testing 2008: https://www.bhiva.org/HIV-testing-guidelines.
[90]
Walker, Z. et al. 2015. Lewy body dementias. The Lancet. 386, 10004 (Oct. 2015), 1683–1697. DOI:https://doi.org/10.1016/S0140-6736(15)00462-6.
[91]
Warren, J.D. et al. 2013. Frontotemporal dementia. BMJ. 347, aug12 3 (Aug. 2013), f4827–f4827. DOI:https://doi.org/10.1136/bmj.f4827.
[92]
Weil, R.S. et al. 2017. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies. F1000Research. 6, (Aug. 2017). DOI:https://doi.org/10.12688/f1000research.11725.1.
[93]
Wendorf, K.A. et al. 2017. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clinical Infectious Diseases. 65, 2 (Jul. 2017), 226–232. DOI:https://doi.org/10.1093/cid/cix302.
[94]
Wild, E.J. and Tabrizi, S.J. 2017. Therapies targeting DNA and RNA in Huntington’s disease. The Lancet Neurology. 16, 10 (Oct. 2017), 837–847. DOI:https://doi.org/10.1016/S1474-4422(17)30280-6.
[95]
Woollacott, I.O.C. and Rohrer, J.D. 2016. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Journal of Neurochemistry. 138, (Aug. 2016), 6–31. DOI:https://doi.org/10.1111/jnc.13654.
[96]
Zhou, L. et al. 2013. Viruses and neurodegeneration. Virology Journal. 10, 1 (2013). DOI:https://doi.org/10.1186/1743-422X-10-172.
[97]
2018. Cognitive Impairment Associated with Cancer: A Brief Review. Innovations in Clinical Neuroscience. 15, 1–2 (2018).
[98]
2001. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet. 357, 9251 (Jan. 2001), 169–175. DOI:https://doi.org/10.1016/S0140-6736(00)03589-3.